Dosing down with biologic therapies: a systematic review and clinicians' perspective

Rheumatology (Oxford, England)

Volumn 56, Issue 11, 2017, Pages 1847-1856

  Edwards, Christopher J ^a   Fautrel, Bruno ^a   Schulze Koops, Hendrik ^a   Huizinga, Tom W J ^a   Kruger, Klaus ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

axial spondyloarthritis; biologic therapy; dose spacing; dose tapering; dosing down; psoriatic arthritis; rheumatoid arthritis; systematic review; treatment withdrawal

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMAN; MAINTENANCE CHEMOTHERAPY; REMISSION; SPONDYLARTHROPATHIES;

ABATACEPT; ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; ETANERCEPT; HUMANS; INFLIXIMAB; MAINTENANCE CHEMOTHERAPY; REMISSION INDUCTION; RITUXIMAB; SPONDYLARTHROPATHIES;

EID: 85026245803     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew464     Document Type: Review

References (0)